ArticleMedical oncology (Northwood, London, England)2021
Silencing Akt1 enhances the resistance of prostate cancer cells to starvation and inhibits starvation-induced lung metastasis through epithelial-mesenchymal transition in prostate cancer.
Article in Medical oncology (Northwood, London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 9 citations in OpenAlex.
- [Regulatory Role of the AKT1/AMPK Pathway in Oxidative Stress of Lens Epithelial Cells in Cataract Patients].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025Article
- What should be the future direction of development in the field of prostate cancer with lung metastasis?World journal of clinical oncology · 2023Article
- A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence.Pharmaceuticals (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Nutritional starvation (NST) is the basis of tumor anti-angiogenesis and metabolic therapy strategy. Silencing Akt1 inhibits prostate cancer (PCa) cells growing; slow-growing cells tend to consume less nutrition. It is suggested that Akt1-silenced cancer cells will have a more substantial tolerance to NST. Clarify this critical question is vital for tumor treatment strategies based on Akt1 and NST. The Akt1 gene of PC3 and DU145 cells was silenced by lent-virus. NST model was established by serum stripping. Cell viability was detected by MTT assay and cell counting method. Apoptosis was detected by TUNEL and flow cytometry, and cell invasion was determined by transwells and ECIS. The markers of epithelial-mesenchymal transition (EMT) were detected by western blotting. PCa lung metastasis model was established by tail vein injection and quantified by Indian ink and GFP fluorescence. Silencing Akt1 slowed down the decrease of cell number and increase of apoptosis caused by NST. Silencing Akt1 with NST exposure in PCa cells could down-regulate epithelial markers (E-cadherin, claudin-5, and ZO-1) and up-regulate mesenchymal markers N-cadherin and EMT regulators Snail. Although silencing Akt1 enhanced the invasion of PCa cells induced by NST in vitro, silencing Akt1 inhibited the PCa lung metastasis induced by NST in vivo. Silencing Akt1 gene enhances the resistance of PCa cells to NST. The invasion results in vitro were inconsistent with those metastases in vivo, which may be related to a combination of NST with silencing Akt1 to maintain the mesenchymal state of PCa cells through EMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.